

Mvg 5.1.2e

-----Oorspronkelijk bericht-----

Van: 5.1.2e <5.1.2e@cbg-meb.nl>

Verzonden: maandag 30 maart 2020 12:21

Aan: 5.1.2e <5.1.2e@minvws.nl>

CC: 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@minvws.nl>; 5.1.2e <5.1.2e@cbg-meb.nl>

Onderwerp: Re: 3rd TC with Commissioners COVID-19

Dank hiervoor 5.1.2e

Wij hebben onderstaande lijst idd opgesteld en info gedeeld met EMA.

Groet,

5.1.2e

Van: "5.1.2e" <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>

Datum: maandag 30 maart 2020 om 12:11:33

Aan: "5.1.2e" <5.1.2e@cbg-meb.nl> <5.1.2e@cbg-meb.nl>>

Cc: "5.1.2e" <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>, "5.1.2e" <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>, "5.1.2e" <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>, "5.1.2e" <5.1.2e@minvws.nl> <5.1.2e@minvws.nl>>

Onderwerp: RE: 3rd TC with Commissioners COVID-19

Beste 5.1.2e

In aanvulling op het verslag: beleid in NL is ook om normale hoeveelheden (recept)geneesmiddelen mee te geven in de apotheek aan patiënten (meestal 3 maanden) ook voor paracetamol bij drogist en supermarkt worden beperkte hoeveelheden per klant verkocht zodat andere klanten niet met lege handen komen te staan.

Nog een vraag tav onderstaande, stellen jullie die lijst op?

EMA has asked Member States to define a list of priority medicines used in their territory, based on the list of priority medicines developed by WHO. The medicines included in the consolidated list will be monitored for potential shortages. Follow-up actions could be finding therapeutic alternatives or scaling up of production during the outbreak. Results are due by Monday 30th March, after which EMA will prepare a combined EU list.

Mvg 5.1.2e

5.1.2e <5.1.2e@cbg-meb.nl>

Verzonden: vrijdag 27 maart 2020 09:40

Aan: 5.1.2e <5.1.2e@minvws.nl>

CC: 5.1.2e <5.1.2e@cbg-meb.nl>

Onderwerp: FW: 3rd TC with Commissioners COVID-19

Dag 5.1.2e

Bij deze ter info - in aanvulling op mijn verslag van gisteren.

Vriendelijke groet,

5.1.2e

Van: 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>>

Verzonden: donderdag 26 maart 2020 22:11

Aan: 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>>;

5.1.2e <5.1.2e@bvl.bund.de> <5.1.2e@bvl.bund.de>; 5.1.2e <5.1.2e@ema.europa.eu> <5.1.2e@ema.europa.eu>>; 5.1.2e <5.1.2e@cbg-

meb.nl< 5.1.2e @cbg-meb.nl>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>;
 5.1.2e @aemps.es< 5.1.2e @aemps.es>; 5.1.2e @anses.fr< 5.1.2e @anses.fr>;
 5.1.2e @ansm.sante.fr< 5.1.2e @ansm.sante.fr>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>;
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e @bfarm.de< 5.1.2e @bfarm.de>;
 5.1.2e @ec.europa.eu' < 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu>;
 5.1.2e @dkma.dk< 5.1.2e @dkma.dk>; 5.1.2e @ravimiamet.ee< 5.1.2e @ravimiamet.ee>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e < 5.1.2e @cbg-
 mebnl< 5.1.2e @cbg-meb.nl>; 5.1.2e @ansm.sante.fr< 5.1.2e @ansm.sante.fr>;
 5.1.2e @hpra.ie< 5.1.2e @hpra.ie>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>;
 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>
 CC: 5.1.2e < 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e < 5.1.2e @cbg-
 mebnl< 5.1.2e @cbg-meb.nl>; 5.1.2e < 5.1.2e @bfarm.de< 5.1.2e @bfarm.de>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e < 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>>

Onderwerp: FW: 3rd TC with Commissioners COVID-19

Dear colleagues

FYI, please find attached the status report of today's meetings which has been sent to the Commissioners.

Best regards

5.1.2e

Classified as confidential by the European Medicines Agency

From: 5.1.2e < 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>>

Sent: 26 March 2020 22:00

To: 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>;
 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>

Cc: 5.1.2e @ec.europa.eu' < 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>>; 5.1.2e @ec.europa.eu'
 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>;
 5.1.2e @ec.europa.eu>; 5.1.2e @ec.europa.eu' < 5.1.2e @ec.europa.eu< 5.1.2e @ec.europa.eu>>;
 5.1.2e < 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>>; 5.1.2e
 5.1.2e @ema.europa.eu< 5.1.2e @ema.europa.eu>>

Subject: 3rd TC with Commissioners COVID-19

Dear Commissioners,

As indicated at the previous TC, please find attached the "Status Report from the EU Executive Steering Group on shortages caused by major events in relation to supply shortages caused by the COVID-19 infection".

This status report dated 26 March 2020 takes into account the feedback received from all EU Industry Associations up to 26 March. Such feedback was discussed at today's meeting of the aforementioned Steering Group. Actions agreed by the Steering Group at today's meeting, as well as actions recently undertaken at the level of the EU Regulatory Authorities are also described in the status report. The status report will also be circulated to all EU Industry Associations this evening.

Kind regards,

[3-EMA banner - option 1]<https://www.ema.europa.eu/en/about-us/history-ema>

5.1.2e

European Medicines Agency

European Medicines Agency

Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands Telephone +31 (0)88 5.1.2e | Mobile +31 (0)6 5.1.2e
5.1.2e@ema.europa.eu <5.1.2e@ema.europa.eu> | www.ema.europa.eu <https://www.ema.europa.eu/en>
| For directions, see How to find us <https://www.ema.europa.eu/en/about-us/contact/how-find-us>

Follow us: [Twitter-icon] <https://twitter.com/EMA_News> [RSS-icon] <https://www.ema.europa.eu/en/news-event/rss-feeds> [Youtube-icon] <https://www.youtube.com/user/emainfo>

This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately.

Classified as confidential by the European Medicines Agency

This e-mail has been scanned for all known viruses by European Medicines Agency.

This inbound message has been checked for all known viruses by KPN's Secure Information Exchange service, powered by Symantec.cloud.
